TRDA

Over the past six months, Entrada Therapeutics' stock experienced a significant drop of 57.27% around May 2026, coinciding with a Q1 loss and missed revenue estimates. In June 2026, the Independent Safety Data Monitoring Committee recommended initiating Cohort 2 at an increased dose in the ELEVATE-45-201 study, which was followed by a -3.91% change in stock price. August 2026 saw a -2.49% stock price change after the company reported a Q2 loss but topped revenue estimates. In September 2026, the stock changed by -9.70% following the announcement of its Fourth Annual DREAMS Grant Program recipients, and by -1.78% after announcing inducement grants. A Schedule 13D/A filing in September also indicated that nearly 10% of the company is held by one venture group.